Jan. 21 at 4:50 AM
$WGS I struggle with the ‘interpretation is the moat’ argument. GeneDx doesn’t own the genomes, doesn’t build the machines, and relies on sequencing done by others. As sequencing costs move well below
$100, that layer will only get more competitive. Hard to see what’s truly owned here — and worth watching how much of current profitability reflects timing and accounting rather than durable economics.
